Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Biliary Cirrhosis (PBC)
Conditions
Primary Biliary Cirrhosis (PBC)
Trial Timeline
Nov 4, 2015 → Jul 1, 2016
NCT ID
NCT02609048About Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mg is a phase 2 stage product being developed by Gilead Sciences for Primary Biliary Cirrhosis (PBC). The current trial status is terminated. This product is registered under clinical trial identifier NCT02609048. Target conditions include Primary Biliary Cirrhosis (PBC).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02609048 | Phase 2 | Terminated |
Competing Products
20 competing products in Primary Biliary Cirrhosis (PBC)